Publications by authors named "A Weevers"
Background: Respiratory dysfunction is an important contributor to morbidity and mortality in advanced Parkinson's disease (PD), but it is unclear what parameters are sensitive to diagnose and monitor respiratory dysfunction across disease phases.
Objectives: We aimed to characterize respiratory dysfunction in mild to moderate PD.
Methods: In 20 individuals without cardiopulmonary comorbidity, pulmonary and inspiratory muscle function testing were performed ON-medication.
Analyses from administrative databases have suggested an increased cancer incidence among individuals who experienced a myocardial infarction, especially within the first 6 months. It remains unclear to what extent this represents an underlying biological link, or can be explained by detection of pre-symptomatic cancers and shared risk factors. Cancer incidence among 1809 consecutive patients surviving hospitalization for thrombotic ST-segment-elevation myocardial infarction (STEMI; mean age 62.
View Article and Find Full Text PDFBackground: Randomized controlled trials for in-stent restenosis (ISR) and de novo lesions in small-diameter vessels have shown promising results, but data on DCB use in real-world practice are still scarce. The aim of the PEARL (Paclitaxel-Eluting Angioplasty Balloon in the Real-World) registry was to evaluate the safety and efficacy of a paclitaxel DCB in real-world percutaneous coronary intervention (PCI) practice.
Methods: Between 2014 and 2019, a total of 513 patients treated with the Protégé paclitaxel DCB (Wellinq) were prospectively included at 4 hospitals in the Netherlands.
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
EuroIntervention
March 2022
Article Synopsis
- The study examined the long-term (five-year) clinical outcomes of the Absorb bioresorbable vascular scaffold (BVS) compared to the XIENCE everolimus-eluting stent (EES) in patients with coronary artery disease.
- There was no significant difference in target vessel failure rates between the two devices; however, the Absorb BVS had a notably higher incidence of device thrombosis (4.8% vs. 1.5% for XIENCE).
- The use of prolonged dual antiplatelet therapy (DAPT) appeared to reduce the risk of scaffold thrombosis over the five-year follow-up period.
Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Catheter Cardiovasc Interv
October 2021
Article Synopsis
- - The study compares the effectiveness of absorb bioresorbable vascular scaffolds (BVS) and Xience everolimus-eluting stents (EES) in patients with diabetes mellitus (DM) during routine percutaneous coronary interventions (PCI) over a 3-year period.
- - Among 1,845 participants, rates of target vessel failure (TVF) were similar for both devices in diabetic patients, but Absorb BVS showed significantly higher rates of device thrombosis compared to Xience EES for both diabetic and nondiabetic patients.
- - Overall, both Absorb BVS and Xience EES yielded poorer outcomes for diabetic patients, with Absorb BVS being linked to increased risk of device thromb